Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PRRX1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRRX1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRRX1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PRRX1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRRX1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001982713 | Oral cavity | EOLP | stem cell population maintenance | 38/2218 | 131/18723 | 9.10e-08 | 3.15e-06 | 38 |
GO:003109923 | Oral cavity | EOLP | regeneration | 50/2218 | 198/18723 | 1.30e-07 | 4.25e-06 | 50 |
GO:009872713 | Oral cavity | EOLP | maintenance of cell number | 38/2218 | 134/18723 | 1.74e-07 | 5.61e-06 | 38 |
GO:001097515 | Oral cavity | EOLP | regulation of neuron projection development | 86/2218 | 445/18723 | 2.75e-06 | 6.05e-05 | 86 |
GO:00311021 | Oral cavity | EOLP | neuron projection regeneration | 15/2218 | 60/18723 | 3.58e-03 | 2.03e-02 | 15 |
GO:00705701 | Oral cavity | EOLP | regulation of neuron projection regeneration | 10/2218 | 33/18723 | 3.76e-03 | 2.10e-02 | 10 |
GO:001982721 | Oral cavity | NEOLP | stem cell population maintenance | 34/2005 | 131/18723 | 6.89e-07 | 1.93e-05 | 34 |
GO:003109931 | Oral cavity | NEOLP | regeneration | 45/2005 | 198/18723 | 7.52e-07 | 2.10e-05 | 45 |
GO:009872721 | Oral cavity | NEOLP | maintenance of cell number | 34/2005 | 134/18723 | 1.21e-06 | 3.13e-05 | 34 |
GO:001097521 | Oral cavity | NEOLP | regulation of neuron projection development | 77/2005 | 445/18723 | 1.44e-05 | 2.53e-04 | 77 |
GO:00971501 | Oral cavity | NEOLP | neuronal stem cell population maintenance | 9/2005 | 20/18723 | 1.02e-04 | 1.23e-03 | 9 |
GO:00485686 | Oral cavity | NEOLP | embryonic organ development | 71/2005 | 427/18723 | 1.12e-04 | 1.34e-03 | 71 |
GO:00614482 | Oral cavity | NEOLP | connective tissue development | 46/2005 | 252/18723 | 2.11e-04 | 2.25e-03 | 46 |
GO:0060840 | Oral cavity | NEOLP | artery development | 23/2005 | 100/18723 | 3.00e-04 | 2.97e-03 | 23 |
GO:00311022 | Oral cavity | NEOLP | neuron projection regeneration | 16/2005 | 60/18723 | 4.28e-04 | 3.91e-03 | 16 |
GO:0048844 | Oral cavity | NEOLP | artery morphogenesis | 18/2005 | 74/18723 | 6.49e-04 | 5.47e-03 | 18 |
GO:0051216 | Oral cavity | NEOLP | cartilage development | 32/2005 | 190/18723 | 6.44e-03 | 3.32e-02 | 32 |
GO:00487051 | Oral cavity | NEOLP | skeletal system morphogenesis | 36/2005 | 220/18723 | 6.47e-03 | 3.33e-02 | 36 |
GO:0048701 | Oral cavity | NEOLP | embryonic cranial skeleton morphogenesis | 11/2005 | 46/18723 | 7.99e-03 | 3.95e-02 | 11 |
GO:00198278 | Skin | AK | stem cell population maintenance | 37/1910 | 131/18723 | 5.65e-09 | 4.03e-07 | 37 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRRX1 | SNV | Missense_Mutation | | c.587N>T | p.Ala196Val | p.A196V | P54821 | protein_coding | tolerated(0.06) | benign(0.142) | TCGA-A8-A096-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRRX1 | SNV | Missense_Mutation | | c.96G>T | p.Lys32Asn | p.K32N | P54821 | protein_coding | deleterious(0.01) | probably_damaging(0.981) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRRX1 | SNV | Missense_Mutation | | c.284N>A | p.Arg95Gln | p.R95Q | P54821 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-BH-A18F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
PRRX1 | SNV | Missense_Mutation | | c.526G>C | p.Glu176Gln | p.E176Q | P54821 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PRRX1 | SNV | Missense_Mutation | novel | c.434N>A | p.Arg145Gln | p.R145Q | P54821 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-E2-A154-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PRRX1 | SNV | Missense_Mutation | rs761253714 | c.484N>A | p.Ala162Thr | p.A162T | P54821 | protein_coding | tolerated(0.07) | benign(0.236) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PRRX1 | SNV | Missense_Mutation | | c.587C>T | p.Ala196Val | p.A196V | P54821 | protein_coding | tolerated(0.06) | benign(0.142) | TCGA-E9-A1RE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
PRRX1 | SNV | Missense_Mutation | | c.257N>T | p.Ser86Leu | p.S86L | P54821 | protein_coding | tolerated(0.08) | benign(0.011) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
PRRX1 | SNV | Missense_Mutation | novel | c.434N>A | p.Arg145Gln | p.R145Q | P54821 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRRX1 | SNV | Missense_Mutation | novel | c.445T>C | p.Phe149Leu | p.F149L | P54821 | protein_coding | deleterious(0) | possibly_damaging(0.757) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |